BORTEZOMIB-BASED THERAPY IN FRAIL MULTIPLE MYELOMA PATIENTS

被引：0
|
作者：
Antonioli, E.
Staderini, M.
Nozzoli, C.
Bacchiarri, F.
Barone, F.
Grieco, P.
Coltro, G.
Guarrera, A.
Messeri, M.
Bosi, A.
机构：
[1] Azienda Osped Univ Careggi, SODC Ematol, Careggi, Italy
[2] Azienda Osped Univ Careggi, SOD Terapie Cellulari & Med Trasfus, Careggi, Italy
来源：
HAEMATOLOGICA | 2017年 / 102卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P202
引用
收藏
页码：132 / 132
页数：1
相关论文
共 50 条
  • [1] Thrombotic microangiopathy complicating bortezomib-based therapy for multiple myeloma
    Chan, Kah-Lok
    Filshie, Robin
    Nandurkar, Harshal
    Quach, Hang
    [J]. LEUKEMIA & LYMPHOMA, 2015, 56 (07) : 2185 - 2186
  • [2] Results of the first bortezomib-based induction therapy in the treatment of multiple myeloma
    Kortuem, Martin
    Einsele, Hermann
    [J]. EXPERT OPINION ON PHARMACOTHERAPY, 2011, 12 (10) : 1661 - 1663
  • [3] Clinical outcomes of bortezomib-based therapy in myeloma
    Djebbari, Faouzi
    Srinivasan, Anandagopal
    Valiance, Grant
    Moore, Sally
    Kothari, Jaime
    Ramasamy, Karthik
    [J]. PLOS ONE, 2018, 13 (12):
  • [4] Superior myeloma response with bortezomib-based regimen in multiple myeloma patients with renal impairment
    Bao, Li
    Lu, Jin
    Wang, Shihua
    Huang, Xiaojun
    [J]. INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2016, 9 (03): : 6200 - 6209
  • [5] Bortezomib-based consolidation or maintenance therapy for multiple myeloma: a meta-analysis
    Shijia Zhang
    Amit A. Kulkarni
    Beibei Xu
    Haitao Chu
    Taxiarchis Kourelis
    Ronald S. Go
    Michael L. Wang
    Veronika Bachanova
    Yucai Wang
    [J]. Blood Cancer Journal, 10
  • [6] Bortezomib-based consolidation or maintenance therapy for multiple myeloma: a meta-analysis
    Zhang, Shijia
    Kulkarni, Amit A.
    Xu, Beibei
    Chu, Haitao
    Kourelis, Taxiarchis
    Go, Ronald S.
    Wang, Michael L.
    Bachanova, Veronika
    Wang, Yucai
    [J]. BLOOD CANCER JOURNAL, 2020, 10 (03)
  • [7] BORTEZOMIB-BASED REGIMENS AS INDUCTION AND MAINTENANCE TREATMENT IN MULTIPLE MYELOMA (MM) PATIENTS NOT ELIGIBLE FOR AGGRESSIVE THERAPY
    Mazzone, C.
    Gentile, M.
    Vigna, E.
    Lucia, E.
    Lorio, C.
    Morelli, R.
    Bisconte, M. G.
    Gentile, C.
    Morabito, F.
    [J]. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 544 - 544
  • [8] The Value of Serum MicroRNA Expression Signature in Predicting Refractoriness to Bortezomib-Based Therapy in Multiple Myeloma Patients
    Robak, Pawel
    Drozdz, Izabela
    Jarych, Dariusz
    Mikulski, Damian
    Weglowska, Edyta
    Siemieniuk-Rys, Monika
    Misiewicz, Malgorzata
    Stawiski, Konrad
    Fendler, Wojciech
    Szemraj, Janusz
    Smolewski, Piotr
    Robak, Tadeusz
    [J]. CANCERS, 2020, 12 (09) : 1 - 18
  • [9] Patterns of Relapse or Progression After Bortezomib-Based Salvage Therapy in Patients With Relapsed/Refractory Multiple Myeloma
    Ahn, Jae-Sook
    Jung, Sung-Hoon
    Yang, Deok-Hwan
    Bae, Soo-Young
    Kim, Yeo-Kyeoung
    Kim, Hyeoung-Joon
    Lee, Je-Jung
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2014, 14 (05): : 389 - 394
  • [10] Feasibility and Activity Of Bortezomib-Based Therapy In Patients With Relapsed/Refractory Multiple Myeloma Previously Treated With Carfilzomib
    Alagappan, Arti
    Shah, Rupin A.
    Thomas, Sheeba K.
    Weber, Donna M.
    Wang, Michael
    Alexanian, Raymond
    Orlowski, Robert Z.
    Shah, Jatin J.
    [J]. BLOOD, 2013, 122 (21)
12345